{"id":52880,"date":"2026-01-05T21:52:06","date_gmt":"2026-01-05T13:52:06","guid":{"rendered":"https:\/\/flcube.com\/?p=52880"},"modified":"2026-01-05T21:52:07","modified_gmt":"2026-01-05T13:52:07","slug":"geneditbios-geb-101-wins-fda-ind-approval-as-worlds-first-corneal-gene-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52880","title":{"rendered":"GenEditBio&#8217;s GEB-101 Wins FDA IND Approval as World&#8217;s First Corneal Gene Therapy"},"content":{"rendered":"\n<p><strong>GenEditBio<\/strong> announced that <strong>GEB-101<\/strong>, its self\u2011developed <strong>in vivo genome editing investigational drug<\/strong>, has received <strong>Investigational New Drug (IND) approval<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong>, becoming the <strong>world\u2019s first genome\u2011editing therapy<\/strong> targeting <strong>TGFBI\u2011linked corneal dystrophy<\/strong>, a rare autosomal dominant disorder causing progressive vision loss and severe ocular pain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-milestone\">Regulatory &amp; Product Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>GEB-101 (in vivo genome editing therapy)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>GenEditBio (China\u2011based)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA IND approval granted<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>TGFBI\u2011linked corneal dystrophy<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>CRISPR\u2011based editing of mutant TGFBI gene<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td><strong>First\u2011in\u2011world<\/strong> to address underlying genetic cause<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Localized corneal delivery (injection or drops)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-background-amp-unmet-need\">Disease Background &amp; Unmet Need<\/h2>\n\n\n\n<p><strong>TGFBI\u2011Linked Corneal Dystrophy<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: <strong>~50,000\u201160,000<\/strong> patients in China; <strong>10,000\u201115,000<\/strong> in US\/EU<\/li>\n\n\n\n<li><strong>Pathophysiology<\/strong>: Mutations in <strong>TGFBI gene<\/strong> cause <strong>abnormal protein deposition<\/strong> in cornea, leading to <strong>photophobia, recurrent severe eye pain, and progressive vision loss<\/strong><\/li>\n\n\n\n<li><strong>Current Treatments<\/strong>: <strong>Phototherapeutic keratectomy (PTK)<\/strong> or <strong>corneal transplants<\/strong><\/li>\n\n\n\n<li><strong>Limitations<\/strong>: Provide only <strong>short\u2011term relief<\/strong>; cannot prevent <strong>re\u2011accumulation<\/strong> of abnormal proteins<\/li>\n\n\n\n<li><strong>Recurrence Rate<\/strong>: <strong>40\u201160%<\/strong> within 5\u201110 years, forcing <strong>repeated surgeries<\/strong><\/li>\n\n\n\n<li><strong>Quality of Life<\/strong>: Patients endure <strong>chronic pain cycles<\/strong> and <strong>gradual vision deterioration<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Gap<\/strong>: <strong>No disease\u2011modifying therapy<\/strong> exists; GEB-101 aims to <strong>halt disease progression at the genetic source<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-in-vivo-genome-editing\">Technology Profile: In Vivo Genome Editing<\/h2>\n\n\n\n<p><strong>Mechanism of Action<\/strong>: GEB-101 utilizes <strong>CRISPR\u2011based genome editing<\/strong> to precisely <strong>correct mutant TGFBI alleles<\/strong> in corneal epithelial cells, preventing synthesis of abnormal protein deposits.<\/p>\n\n\n\n<p><strong>Key Advantages Over Surgery<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>GEB-101 (Gene Editing)<\/th><th>PTK\/Transplant (Standard of Care)<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td><strong>Underlying genetic mutation<\/strong><\/td><td>Surface protein deposits only<\/td><\/tr><tr><td><strong>Durability<\/strong><\/td><td><strong>Potential one\u2011time curative effect<\/strong><\/td><td>Temporary (40\u201160% recurrence)<\/td><\/tr><tr><td><strong>Invasiveness<\/strong><\/td><td><strong>Minimally invasive<\/strong> (local injection\/drops)<\/td><td>Highly invasive (surgery)<\/td><\/tr><tr><td><strong>Recovery<\/strong><\/td><td>Days to weeks<\/td><td>Months; risk of graft rejection<\/td><\/tr><tr><td><strong>Cost<\/strong><\/td><td>Projected <strong>\u00a5300,000\u2011400,000<\/strong> per treatment<\/td><td><strong>\u00a580,000\u2011150,000<\/strong> per surgery (repeat every 5\u201110 years)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Preclinical Data<\/strong>: Demonstrated <strong>&gt;90% correction efficiency<\/strong> of mutant TGFBI alleles in human corneal explants, with <strong>complete cessation of protein deposition<\/strong> and <strong>stable corneal clarity<\/strong> over 12 months in animal models.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>Global Addressable Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US\/EU<\/strong>: <strong>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (US$110\u2011170M) peak potential by 2032<\/li>\n\n\n\n<li><strong>China<\/strong>: <strong>\u00a51.5\u20112.0\u202fbillion<\/strong> (US$210\u2011280M) peak potential<\/li>\n\n\n\n<li><strong>Combined<\/strong>: <strong>\u00a52.3\u20113.2\u202fbillion<\/strong> (US$320\u2011450M) global opportunity<\/li>\n<\/ul>\n\n\n\n<p><strong>Pricing Strategy<\/strong>: Premium gene therapy pricing justified by <strong>one\u2011time curative potential<\/strong> vs. <strong>multiple surgeries<\/strong> over lifetime.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapy<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage<\/th><th>Durability<\/th><\/tr><\/thead><tbody><tr><td><strong>GEB-101<\/strong><\/td><td><strong>GenEditBio<\/strong><\/td><td>In vivo CRISPR editing<\/td><td><strong>Phase\u202fI ready<\/strong><\/td><td><strong>Potentially lifelong<\/strong><\/td><\/tr><tr><td><strong>PTK<\/strong><\/td><td>Various<\/td><td>Laser ablation<\/td><td>Marketed<\/td><td>5\u201110 years (recurrence)<\/td><\/tr><tr><td><strong>Corneal Transplant<\/strong><\/td><td>Various<\/td><td>Allograft replacement<\/td><td>Marketed<\/td><td>10\u201115 years (rejection risk)<\/td><\/tr><tr><td><strong>AAV\u2011mediated TGFBI knockdown<\/strong><\/td><td>Preclinical<\/td><td>Gene therapy<\/td><td>Pre\u2011clinical<\/td><td>Unknown<\/td><\/tr><tr><td><strong>Small molecule chaperones<\/strong><\/td><td>Preclinical<\/td><td>Protein stabilization<\/td><td>Pre\u2011clinical<\/td><td>Limited efficacy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: GEB-101 is <strong>24\u201136 months ahead<\/strong> of any competitor in corneal gene editing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Target Date<\/th><th>Key Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202fI Initiation<\/strong><\/td><td>Q1\u202f2026<\/td><td>Safety, tolerability, initial efficacy signals<\/td><\/tr><tr><td><strong>Phase\u202fII<\/strong><\/td><td>Q4\u202f2026<\/td><td>Efficacy on corneal clarity, pain reduction<\/td><\/tr><tr><td><strong>Phase\u202fIII<\/strong><\/td><td>Q4\u202f2027<\/td><td>Confirmatory trial vs. surgical standard of care<\/td><\/tr><tr><td><strong>BLA Filing<\/strong><\/td><td>Q2\u202f2029<\/td><td>Rolling submission to FDA<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>2030<\/td><td>US\/EU launch; China partnership discussions<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Orphan Drug Strategy<\/strong>: Eligible for <strong>Orphan Drug Designation<\/strong> in US\/EU (prevalence &lt;200,000), providing <strong>7\u201110 year market exclusivity<\/strong> and <strong>tax incentives<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding GEB-101\u2019s clinical development pathway, market opportunity, regulatory strategy, and peak sales potential. Actual results may differ materially due to clinical trial outcomes, competitive responses, manufacturing scale\u2011up challenges, and regulatory review timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GenEditBio announced that GEB-101, its self\u2011developed in vivo genome editing investigational drug, has received Investigational&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52895,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,66,4525,44],"class_list":["post-52880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-gene-therapy","tag-geneditbio","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenEditBio&#039;s GEB-101 Wins FDA IND Approval as World&#039;s First Corneal Gene Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GenEditBio announced that GEB-101, its self\u2011developed in vivo genome editing investigational drug, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), becoming the world\u2019s first genome\u2011editing therapy targeting TGFBI\u2011linked corneal dystrophy, a rare autosomal dominant disorder causing progressive vision loss and severe ocular pain.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52880\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenEditBio&#039;s GEB-101 Wins FDA IND Approval as World&#039;s First Corneal Gene Therapy\" \/>\n<meta property=\"og:description\" content=\"GenEditBio announced that GEB-101, its self\u2011developed in vivo genome editing investigational drug, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), becoming the world\u2019s first genome\u2011editing therapy targeting TGFBI\u2011linked corneal dystrophy, a rare autosomal dominant disorder causing progressive vision loss and severe ocular pain.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52880\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T13:52:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T13:52:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenEditBio&#8217;s GEB-101 Wins FDA IND Approval as World&#8217;s First Corneal Gene Therapy\",\"datePublished\":\"2026-01-05T13:52:06+00:00\",\"dateModified\":\"2026-01-05T13:52:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880\"},\"wordCount\":560,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0502.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Gene therapy\",\"GenEditBio\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52880#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52880\",\"name\":\"GenEditBio's GEB-101 Wins FDA IND Approval as World's First Corneal Gene Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0502.webp\",\"datePublished\":\"2026-01-05T13:52:06+00:00\",\"dateModified\":\"2026-01-05T13:52:07+00:00\",\"description\":\"GenEditBio announced that GEB-101, its self\u2011developed in vivo genome editing investigational drug, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), becoming the world\u2019s first genome\u2011editing therapy targeting TGFBI\u2011linked corneal dystrophy, a rare autosomal dominant disorder causing progressive vision loss and severe ocular pain.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52880\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0502.webp\",\"width\":1080,\"height\":608,\"caption\":\"GenEditBio's GEB-101 Wins FDA IND Approval as World's First Corneal Gene Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52880#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenEditBio&#8217;s GEB-101 Wins FDA IND Approval as World&#8217;s First Corneal Gene Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenEditBio's GEB-101 Wins FDA IND Approval as World's First Corneal Gene Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"GenEditBio announced that GEB-101, its self\u2011developed in vivo genome editing investigational drug, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), becoming the world\u2019s first genome\u2011editing therapy targeting TGFBI\u2011linked corneal dystrophy, a rare autosomal dominant disorder causing progressive vision loss and severe ocular pain.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52880","og_locale":"en_US","og_type":"article","og_title":"GenEditBio's GEB-101 Wins FDA IND Approval as World's First Corneal Gene Therapy","og_description":"GenEditBio announced that GEB-101, its self\u2011developed in vivo genome editing investigational drug, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), becoming the world\u2019s first genome\u2011editing therapy targeting TGFBI\u2011linked corneal dystrophy, a rare autosomal dominant disorder causing progressive vision loss and severe ocular pain.","og_url":"https:\/\/flcube.com\/?p=52880","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-05T13:52:06+00:00","article_modified_time":"2026-01-05T13:52:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52880#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52880"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenEditBio&#8217;s GEB-101 Wins FDA IND Approval as World&#8217;s First Corneal Gene Therapy","datePublished":"2026-01-05T13:52:06+00:00","dateModified":"2026-01-05T13:52:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52880"},"wordCount":560,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52880#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0502.webp","keywords":["Clinical trial approval \/ initiation","Gene therapy","GenEditBio","Ophthalmology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52880#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52880","url":"https:\/\/flcube.com\/?p=52880","name":"GenEditBio's GEB-101 Wins FDA IND Approval as World's First Corneal Gene Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52880#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52880#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0502.webp","datePublished":"2026-01-05T13:52:06+00:00","dateModified":"2026-01-05T13:52:07+00:00","description":"GenEditBio announced that GEB-101, its self\u2011developed in vivo genome editing investigational drug, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), becoming the world\u2019s first genome\u2011editing therapy targeting TGFBI\u2011linked corneal dystrophy, a rare autosomal dominant disorder causing progressive vision loss and severe ocular pain.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52880#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52880"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52880#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0502.webp","width":1080,"height":608,"caption":"GenEditBio's GEB-101 Wins FDA IND Approval as World's First Corneal Gene Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52880#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenEditBio&#8217;s GEB-101 Wins FDA IND Approval as World&#8217;s First Corneal Gene Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52880"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52880\/revisions"}],"predecessor-version":[{"id":52896,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52880\/revisions\/52896"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52895"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}